Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain

Amber Tong

Paul Schloesser

Associate Editor

Apellis Pharmaceuticals still can’t pinpoint exactly what’s behind the rare cases of eye inflammation that’s been reported in patients taking its geographic atrophy drug Syfovre …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain

Amber Tong

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Associate Editor

Sign up to read this article for free.

Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain